Biomx Inc. · AMEX:PHGE
Biomx — Investor Presentation (November 2025)
26 slides from Biomx's investor presentation, November 2025
Slide 1: Corporate Presentation November 2025
Clinical Stage Programs Addressing Urgent Need for Overcoming Antibiotic Resistance Corporate Presentation November 2025 NYSE American: PHGE
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT About this Presentation The information contained in this presentation has been prepared by BiomX Inc. and its subsidiaries (collectively, the “Company” or “BiomX”) and contains information pertaining to the business and operations of the Company. The information contained in t
Slide 3: Antimicrobial Resistance: Rising concerns and limited treatment options
Antimicrobial Resistance: Rising concerns and limited treatment options underscore the urgent need for novel therapies Resistance Rate of 10M 35% S. Aureus to antibiotic Methicillin1 Annual Deaths by 2050 WHO projected Antimicrobial Resistance Mortality3 Increase in Death Associated 70% with Antimic
Slide 4: Phage Therapy: A century-old solution with renewed promise
Phage Therapy: A century-old solution with renewed promise Key Advantages Active against Targets Only Self-Amplifying Ability to Launch Safe Modality, Harmful Bacteria Penetrates and Straight into Antibiotic Phages Increase Inert to Human – No Disruption Disrupts Biofilm Early/Mid Clinical Resistant
Slide 5: Phage Therapy Momentum: Growing clinical data signal a pivotal moment ahead
Phage Therapy Momentum: Growing clinical data signal a pivotal moment ahead1 March 2025: BiomX positive P2 data Nov. 2023: BiomX positive P1b/2a data 41 patients 43 patients Diabetic Foot Osteomyelitis Cystic Fibrosis Aug. 2024: Peer company reported May 2025: Peer company reported positive P2 Part
Slide 6: Shared Targets, Expanded Potential
Shared Targets, Expanded Potential: Clinical efficacy opens the door to potential additional Phase 2 studies across related infections Phase 2b Cystic Fibrosis – Target: P. aeruginosa Expected readout Q1 2026 BX004 Cystic Fibrosis Phase 2 Ready Non-Cystic November 2023, Positive Phase 2 results Fibr
Slide 7: BiomX's Groundbreaking Phase 2 Results
BiomX's Groundbreaking Phase 2 Results Efficacy of phage therapy across indications Cystic Fibrosis (BX004): Diabetic Foot Osteomyelitis (BX211): On top of antibiotic SoC On top of antibiotic SoC -2.91 log10 CFU/g Demonstration of ability of phage to convert chronic lung The 1st multi-center, double
Slide 8: BiomX—Built on a Strong Foundation
BiomX—Built on a Strong Foundation: Backed by leaders in science, industry, and capital Strong Science & Scientific Founders Prof. Rotem Sorek Prof. Eran Elinav Prof. Timothy K. Lu Dr. Carl Merril Head of microbial genomics group Principal investigator at Weizmann Associate professor leading synthet
Slide 9: Cystic Fibrosis and BX004
BX004 Cystic Fibrosis and NCFB
Slide 10: Cystic Fibrosis: Chronic pulmonary infections primary causes of death
Cystic Fibrosis: Chronic pulmonary infections and the inflammatory response are primary causes of death in CF Cystic Fibrosis Thickened Thick, sticky mucus traps bacteria and hinders Thick mucus promotes Mucus normal airway clearance, fostering chronic lung chronic bacteria infections, often driven
Slide 11: Phase 1b/2a Study Design
Phase 1b/2a Study Design: Multicentered, double blind, placebo- controlled study to assess safety, reduction of PsA burden and improvement in clinical outcomes Part 11 Part 2 Enrollment: BX004 7 days - Single 10 days of same ascending dose followed dose, twice daily 43 CF patients by multiple doses2
Slide 12: Results Highlight: Phase 1b/2a cystic fibrosis
Results Highlight: Phase 1b/2a cystic fibrosis (Part 1 and 2) Study drug was well-tolerated Reduction in bacterial load Culture conversion Clinical efficacy Part 1, at Day 15: 2.7 log₁₀ CFU/g Part 2, in the BX004 arm, 3 of 21 BX004 showed signals of treatment effect (represents (14.3%) patients conv
Slide 13: Efficacy (1): BX004 greater reduction in PsA levels vs placebo
Efficacy (1): BX004 demonstrated greater reduction in PsA levels compared to placebo PART 1 (on top of antibiotic SoC): PART 2 (on top of antibiotic SoC, continuous subgroup): -2.91 log10 CFU/g Treatment Follow up Treatment Follow up Day CFU/g log change from Baseline: Mean (SE) CFU/g log change fro
Slide 14: Efficacy (2): BX004 showed greater culture conversion
Efficacy (2): BX004 showed greater conversion (bacterial culture turned negative) in treatment over placebo In the BX004 arm 3 out of 21 (14.3%) patients converted to sputum culture negative for P. aeruginosa after 10 days of treatment (2 already after 4 days)2. In the placebo arm 0 out of 10 (0%)2
Slide 15: Efficacy (3): BX004 clinical improvement after 10 days
Efficacy (3): BX004 shows meaningful clinical improvement after 10 days of treatment in multiple clinical readouts 1 ppFEV1 CFQR (respiratory) Treatment Follow up Treatment Follow up BX004 BX004 Clinical improvements Placebo Placebo were observed on both # objective & patient reported outcomes 5.67%
Slide 16: Phase 2b Study: Study design
Phase 2b Study: Study design International, multicenter, double blind, placebo-controlled study to assess reduction of PsA burden and improvement in clinical outcome Part 2b BX004 2 months of same dose, Enrollment: twice daily Objective: ~60 CF patients1 with chronic PsA infections 2 months 6 months
Slide 17: Non-Cystic Fibrosis Bronchiectasis: Market Expansion Potential
Non-Cystic Fibrosis Bronchiectasis: Market Expansion Potential CF and NCFB have similar lung structural abnormalities These structural abnormalities predispose patients to Pseudomonas aeruginosa infections1 ~25% of NCFB patients have chronic P. aeruginosa infections Physicians treat both CF and NCFB
Slide 18: BX211 Diabetic Foot Infections & Diabetic Foot Osteomyelitis
BX211 Diabetic Foot Infections & Diabetic Foot Osteomyelitis (DFI & DFO)
Slide 19: Disease Burden: DFI & DFO drive diabetic amputations
Disease Burden: DFI & DFO drive diabetic amputations, burdening the healthcare system DFI to DFO Staphylococcus aureus is Bacterial infection the most common bacteria spreading from soft present in DFI / DFO tissue to bone Superficial ulcer DFI DFO Standard of Care Moderate-to-severe DFI & DFO SoC:
Slide 20: Phase 2 Study Design
Phase 2 Study Design: Multicenter, double blind, placebo- controlled study to assess improvement of clinical outcomes Primary Endpoint: Percent area reduction of study ulcer through Week 13 Duration: 12 weeks of once weekly treatment Enrollment: BX211 IV in week 1, topical for 12 weeks Week 13 Week
Slide 21: Results Highlight: Phase 2 diabetic foot osteomyelitis
Results Highlight: Phase 2 diabetic foot osteomyelitis Statistically significant Safe and well-tolerated improvements in ulcer depth in patients with ulcers at bone depth Sustained and statistically significant PAR ulcer size Favorable trends reduction1 compared to placebo Separation from placebo
Slide 22: Efficacy (1): BX211 reduction in ulcer surface area
Efficacy (1): BX211 showed clinically relevant, statistically significant1, reduction in ulcer surface area Percent Area Reduction (PAR) from baseline of ulcer surface area (LS Mean ± SE)2 (See detailed data in next slide) P=0.046 P=0.052 >40% Group Placebo BX211 1. Not adjusted 2. Areas colored in
Slide 23: Efficacy (2): BX211 reduction in ulcer surface area
Efficacy (2): BX211 showed clinically relevant, statistically significant2, reduction in ulcer surface area Percent Area Reduction (PAR) from baseline of ulcer surface area (LS Mean ± SE)1 (Detailed data from previous slide) BX211 Placebo PAR at week: Difference (95% CI) P-value2 N (%) Mean (95% CI)
Slide 24: Efficacy (3): Better recovery at bone depth in BX211 group
Efficacy (3): Patients with ulcers at bone depth1 displayed statistically significant2 better recovery in the BX211 group Change in tissue involvement of the ulcer for weeks 1 and 131 Depth Measurement Tissue3 Healed BX211 (N=13) Placebo (N=9) Dermis Below Dermis Week 1 Week 13 Week 1 Week 13 Bone 1
Slide 25: Summary
Summary
Slide 26: Reputable Investors & Partners
Reputable Investors & ≥ $215 M Partners 3 Patent Raised Families ~$40M Non-Dilutive Robust Scientific Expertise 2 Phage Therapy ≥ 50% PhDs in Leadership Programs Strong 2 Phase 2 ≥ $4 B Addressable Manufacturing Studies Market World-wide Capabilities 26